Ante mortem CSF tau levels correlate with post mortem tau pathology in FTLD (S49.001)

Conclusions:Higher CSF p-tau levels are associated with higher cerebral tau burden in FTLD. In vivo detection of AD co-pathology in FTLD may help stratify clinical cohorts with "pure" neuropathology in which CSF p-tau levels may have diagnostic utility. Autopsy-confirmed samples are critical for FTLD biomarker development and validation. Study Supported by: NIH grants NS044266, AG038490, AG015116, AG010124, P01NS053488, P01AG032953, P01AG017586, AG043503, NS088341, Penn Institute on Aging and the Wyncote Foundation.Disclosure: Dr. Irwin has nothing to disclose. Dr. Lleo has nothing to disclose. Dr. McMillan has nothing to disclose. Dr. Wolk has nothing to disclose. Dr. Van Deerlin has nothing to disclose. Dr. Shaw has received personal compensation for activities with Janssen and Eli Lilly as a consultant. Dr. Trojanowksi has received personal compensation for activities with Johnson & Johnson as a speaker and collaborator. Dr. Grossman has received personal compensation for activities with Avid. Dr. Grossman has received personal compensation in an editorial capacity for Neurology. Dr. Grossman has received research support from BMS.

Source: Neurology - April 17, 2017 Category: Neurology Authors: Irwin, D., Lleo, A., McMillan, C., Wolk, D., Van Deerlin, V., Shaw, L., Trojanowski, J., Grossman, M. Tags: Best Of: Aging and Dementia Source Type: research